SCHEMBL3233194

SCHEMBL3233194

COc1c(C)cc(C)cc1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.40
CNR2 P34972 3/20 0.40
KDM4E B2RXH2 2/20 0.36
PKM P14618 1/20 0.36
PDE3B Q13370 3/20 0.36
PDE3A Q14432 3/20 0.36
ALDH1A1 P00352 4/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PYGL P06737 1/20 0.35
CYP2C9 P11712 1/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
USP2 O75604 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238330 0.90 KDM4E (0.49) CNR1CNR2KDM4EPKMALDH1A1
SCHEMBL3241795 0.84 POLB (0.46) CNR1CNR2ALDH1A1LMNAHPGD
SCHEMBL3238743 0.84 KMT2A (0.45) KDM4EALDH1A1HTTNPSR1LMNA
SCHEMBL3233025 0.84 SLC6A9 (0.39) ALDH1A1PYGLCYP2C9LMNAHPGD
SCHEMBL26840793 0.84 RXFP1 (0.38) CNR2KDM4EALDH1A1CYP2C9LMNA
SCHEMBL3238547 0.83 SMN1; SMN2 (0.48) KDM4EALDH1A1HTTLMNAHPGD
SCHEMBL3235817 0.82 TAS1R3 (0.41) CNR2KDM4EPKMALDH1A1HPGD
SCHEMBL8265383 0.82 CTSS (0.44) ALDH1A1HPGDMEN1KMT2AUSP2
SCHEMBL3238315 0.81 ALDH1A1 (0.41) KDM4EPKMALDH1A1LMNAHPGD
SCHEMBL3238424 0.81 CTSS (0.51) ALDH1A1HPGDUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 CNR1 1607/4885CNR2 1581/4885KDM4E 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.